1. Home
  2. BYD vs GRFS Comparison

BYD vs GRFS Comparison

Compare BYD & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boyd Gaming Corporation

BYD

Boyd Gaming Corporation

HOLD

Current Price

$89.29

Market Cap

6.7B

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$7.96

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BYD
GRFS
Founded
1973
1940
Country
United States
Spain
Employees
N/A
25247
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
5.5B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
BYD
GRFS
Price
$89.29
$7.96
Analyst Decision
Hold
Hold
Analyst Count
11
2
Target Price
$91.00
$10.15
AVG Volume (30 Days)
660.9K
639.3K
Earning Date
04-23-2026
07-28-2022
Dividend Yield
0.84%
1.70%
EPS Growth
264.46
N/A
EPS
22.56
N/A
Revenue
$2,626,730,000.00
N/A
Revenue This Year
$1.71
$4.49
Revenue Next Year
$2.74
$6.42
P/E Ratio
$3.80
$18.67
Revenue Growth
9.41
N/A
52 Week Low
$67.67
$6.90
52 Week High
$89.96
$11.14

Technical Indicators

Market Signals
Indicator
BYD
GRFS
Relative Strength Index (RSI) 61.19 42.52
Support Level $80.53 $7.52
Resistance Level N/A $9.78
Average True Range (ATR) 2.00 0.21
MACD 0.26 0.01
Stochastic Oscillator 98.22 12.37

Price Performance

Historical Comparison
BYD
GRFS

About BYD Boyd Gaming Corporation

Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: